The activation of M3 muscarinic receptor reverses liver injury via the Sp1/ IncRNA Gm2199/miR-212 axis

<table>
<thead>
<tr>
<th>Journal: Acta Biochimica et Biophysica Sinica</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID: ABBS-2021-696.R2</td>
</tr>
<tr>
<td>Manuscript Type: Original Article</td>
</tr>
<tr>
<td>Date Submitted by the Author: 01-Mar-2022</td>
</tr>
<tr>
<td>Complete List of Authors: Zhang, Haiying; Hainan Medical University Gao, Ya Liu, Bin Jin, Hao Fan, Li Yang, Xi Gao, Qiang Yu, Yi Guo, Yue Liu, Yan; Hainan Medical University</td>
</tr>
<tr>
<td>Keywords: molecular biology, IncRNA, liver injury</td>
</tr>
</tbody>
</table>
Original Article

The activation of M₃ muscarinic receptor reverses liver injury via the Sp1/lncRNA Gm2199/miR-212 axis

Haiying Zhang¹,†, Yanan Gao¹,†, Bin Liu³, Haobin Jin⁴, Li Fan⁴, Xirui Yang⁴, Qiang Gao⁴, Yi Yu¹, Yueping Guo²,* and Yan Liu¹,*

¹Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Pharmaceutical, Hainan Medical University, Haikou 571199, China, ²Hainan Medical University First Affiliated Hospital of Department of Anesthesiology, Haikou 570102, China, ³Sanya Central Hospital, Sanya 572000, China, and ⁴Department of Pharmacology, Harbin Medical University, Harbin 150081, China

†These authors contributed equally to this work.

*Correspondence address. Tel/Fax: +86-898-66892193; E-mail: liuyan_gyp@163.com (Y.L.) / Tel: +86-13796051710; E-mail: 13796051710@163.com (Y.G.)

Running title: M₃R activation reverses liver injury by regulating Gm2199

Received: 22-Dec-2021
Accepted: 22-Feb-2022

Copyright
The Author(s) 2022. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Abstract
Muscarinic acetylcholine receptors (MRs) play important roles in the regulation of hepatic fibrosis and the receptor agonists and antagonists can affect hepatocyte
proliferation. However, little is known about the impact of M₃R subtypes and associated signaling pathways on liver injury. The aim of this study is to explore the function and mechanism of M₃R in the regulation of liver injury. We evaluate liver injury and detect the changes in related indexes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), hydroxyproline (HYP), and transforming growth factor-β1 (TGF-β1), after administration of an M₃R agonist. Western blot analysis and qRT-PCR show that the transcription factor Sp1 and lncRNA Gm2199 are also changed significantly. Rescue assay is performed to further confirm that M₃R contributes to the progression of hepatocyte proliferation through regulating Sp1 and Gm2199. The activated M₃R can specifically regulate Gm2199 by inhibiting the expression of Sp1. Meanwhile, Gm2199 directly regulates miR-212, and ERK is a potential target of miR-212. Collectively, these findings define a novel mechanism for activating M₃R to reverse liver injury, which affects hepatocyte proliferation through the Sp1/Gm 2199/miR-212/ERK axis.

Key words: liver injury, M₃ muscarinic acetylcholine receptor (M₃R), transcription factor Sp1, lncRNA Gm2199, miR-212

Introduction
Liver injury results from various liver-related diseases, such as excessive drinking, viral infections, radiation damage, and drug effects [1]. Persistent liver injury can further lead to large-scale damage to liver cells, liver fibrosis and irreversible cirrhosis, and even death. Further exploration of the mechanism of liver injury is particularly important for the treatment of related liver diseases.

Existing studies have demonstrated that the activation of muscarinic and nicotinic receptors can modulate hepatocyte functions, but the mechanisms underlying cholinergic regulation of liver injury are unclear [2]. Of the five muscarinic acetylcholine receptors (MRs) designated as M₁R–M₅R, M₃R is the subtype primarily expressed in human and rodent liver [3, 4]. It has been reported that muscarinic receptor subtype-3 gene ablation augments azoxymethane (AOM)-induced murine liver injury. In addition, AOM-induced liver injury is robustly exacerbated in M₃R-deficient mice [5, 6]. These observations provide a proof-of-principle that selectively stimulating M₃R activation to prevent or diminish liver injury is a
therapeutic strategy worthy of further investigation [7].

Long noncoding RNAs (lncRNAs) are a class of endogenous RNA molecules longer than 200 nucleotides in length [8]. These newly recognized regulatory molecules can participate in many fundamental biological processes and pathophysiological events. Although some lncRNAs have been documented to participate in the development of liver injury [9, 10], the possible roles of these noncoding RNAs and the M₃R of the liver have not been thus far revealed. In our pilot studies, we analyzed the microarray profiling of lncRNA expression in a mouse model of liver injury characterized by hepatic damage manifested by a diminished proliferation capacity of hepatocytes. A multitude of lncRNAs and miRNAs are differentially expressed to significant levels. Among these, Gm2199 stands out as a unique lncRNA that has the potential to impose impacts on the development of liver injury [11]. We therefore carry out this study to explore the role of this lncRNA in regulating liver injury and to decipher the underlying cellular and molecular mechanisms. Unlike lncRNAs, miRNAs are a group of endogenous, evolutionarily conserve non-protein-coding RNA molecules with a typical length of nucleotides [12]. LncRNAs and miRNAs can communicate with and co-regulate each other through competing for endogenous RNAs (ceRNAs) or natural microRNA sponges [13, 14]. In order to provide sufficient elucidation of the complicated ncRNA regulatory network in liver diseases, we screen out absorbed miR-212 from the miRNA pool with differential expression of liver injury based on the sequence characteristics of lncRNA-Gm2199 and further analyze the relationship among the miRNAs screened out for functional verification.

Sp1 is a ubiquitous transcription factor belonging to the zinc finger transcription factor family and is closely related to GC-rich promoter sequences [15]. Sp1 can regulate the expression of many related factors in the liver such as TGF-β1, and then regulates the activation of hepatic stellate cells (HSCs), thereby regulating the occurrence and development of liver fibrosis [16]. Sp1 can also regulate the expression of related lncRNAs, such as the lncRNA-CTBP1-AS2 expression in liver cancer [17]. However, whether Sp1 participates in liver injury by regulating the expression of Gm2199 has yet to be determined.

In this study, we demonstrate for the first time that activation of the M₃R attenuates CCl₄-induced liver injury. The transcription factor Sp1 and Gm2199 are involved in the M₃R-mediated liver injury, which may be an important and potential
new mechanism for the treatment of liver injury.

Materials and Methods

Animals

Male ICR mice (4-week-old) were obtained from the Experimental Animal Center of Harbin Medical University (Harbin, China). All animals were fed under the same conditions, a 12/12 h light/dark cycle and common mouse food and water. Animal testing procedures were approved by the National Institutes of Health's Guide to the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised in 1996). At the same time, all animal experimental protocols were pre-approved by the Experimental Animal Ethics Committee of Harbin Medical University.

Experimental grouping

The effect of pilocarpine (a selective M₃R agonist) and 4-DAMP (an M₃R antagonist) was investigated in a CCl₄-induced liver injury model. ICR mice (n=24) were randomly divided into 4 groups (n=6): control group, mice were treated with soybean oil alone; CCl₄ group, mice were intraperitoneally injected twice a week with CCl₄ (Sigma-Aldrich, Taufkirchen, Germany) at a dose 2.5 mL/kg mixed with 20% (v/v) soybean oil, for 4 weeks; pilocarpine group, mice were treated with the same volume of CCl₄ for 4 weeks, then intraperitoneally administered with pilocarpine (MCE, New Jersey, USA) at a dose of 2.5 mL/kg daily for a total of 2 weeks; 4-DAMP group, mice were first treated with the same volume of CCl₄ for 4 weeks, then treated with 4-DAMP (Sigma-Aldrich, Taufkirchen, Germany) for 30 min at a dose of 1.25 mL/kg, then intraperitoneally administered with pilocarpine at a dose of 2.5 mL/kg daily for a total of 2 weeks.

Liver histopathology

The livers removed from the mice were weighted, and then fixed in 4% paraformaldehyde for 48 h at room temperature. Then, tissues were paraffin-embedded and sectioned into 5-μm pieces, and the liver sections were stained with hematoxylin and eosin (H&E) and Masson’s trichrome (KeyGEN BioTECH, Nanjing, China) using standard protocol for microscopic examination (OLYMPUS, Tokyo, Japan). Morphology and pathology were analyzed by two independent pathologists under blinded conditions.
Measurement of serum levels of ALT and AST

The blood collected from the right ventricle was stored at room temperature for 4 hours, and centrifuged at 1187 g for 10 min, and then the supernatant was separated. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using the corresponding test kits (C009-2 and C010-2; NJBI, Nanjing, China) according to the manufacturer’s instructions.

Measurement of hepatic HYP level

After being washed with sterile phosphate buffered saline (PBS), fresh liver tissues were cut into 80-100 mg samples, dried, accurately weighed, and treated with 1 mL of hydrolyzing reagent provided with the Hydroxyproline (HYP) kit (A030-2; NJBI, Nanjing, China) at 95°C for 20 min. After the pH of the hydrolysate was adjusted to 6.0–6.8, ddH₂O was added to the hydrolysate of each sample to 10 mL. Then, 4 mL of the diluted hydrolysate was filled with 25 mg of activated carbon, mixed and centrifuged at 1616 g for 10 min. Then, 1 mL of the supernatant was dissolved in ddH₂O or 5 μg/mL standard application solution, and then the reacting reagent provided with the HYP assay kit was added and incubated at room temperature and 60 °C for 10 to 15 min. The reaction mixture was then centrifuged at 1616 g for 10 min. Then 200 µL of the supernatant from each sample was dissolved in ddH₂O or 5 μg/mL standard application solution in a 96-well microplate, and the absorbance was measured at 550 nm with a Synergy HTX microplate reader (BioTek Instruments, Winooski, USA). The content of liver HYP is expressed as μg/mg wet liver.

Cell culture and transfection

The mouse AML12 hepatocyte cell line was obtained from American Type Culture Collection (ATCC, Manassas, USA) and cultured in Dulbecco's Modified Eagle's Medium with Nutrient Mixture F-12 (DMEM/F-12) (Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum (FBS), 5 μg/mL human insulin, 5 μg/mL transferrin, 3 ng/ml selenium, 40 ng/ml dexamethasone, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C with 5% CO₂.

Transfections of AML12 cells were carried out using the Lipofectamine 2000 agent (Invitrogen, Carlsbad, USA) following the manufacturer's protocols. miR-212 (mimic-miR-212; 5’-ACCUUG-GCUAGACUCUCUCUCUCUACUTT-3’),
anti-miRNA-212 (AMO-miR-212; 5’-AGUAAGCAGUCUGAGCCAAGGUTT-3’) and negative control (NC; 5’-CUACGGCCAUGACUUGUC-UACUTT-3’) were provided by RiboBio (Guangzhou, China). The empty plasmid (si-NC; sense 5’-UUCUCCGAACGUGUCACGUTT-3’, antisense 5’-ACGUGACACGUUCGGAGAATT-3’) and the interference plasmid (si-Sp1; sense 5’-GCAACAUUAUUGCUGCUAUTT-3’, antisense 5’-AUAGCAGCAAAUAUGUUGCTT-3’) were transfected into cells using lipo2000 (Invitrogen) according to the manufacturer’s instructions. Six hours later, the transfection medium was changed to culture medium supplemented with 10% FBS. After 48 h, AML12 cells were treated with 9 mmol/L CCl₄ for 24 h at 37°C.

For overexpression of Gm2199, plasmid pEGFP-N1 (BglIII/PstI, N0253t, Shanghai Generay Biotech, China) was conjugated with full-length Gm2199 DNA (pEGFP-N1–Gm2199). A pEGFP-N1 conjugated with noting (pEGFP-N1 vector) was kept as a negative control. Cells were incubated in a six-well plate at a density of 1 × 10⁵ per well and a 96-well plate at a density of 4 × 10³ per well before transfection. After 24 h, pEGFP-N1–Gm2199 or pEGFP-N1 vector was transfected into cells using X-treme GENE HP DNA Transfection Reagent (11749800, Roche, Switzerland). All cells were collected after 24 h for the assessments.

**CCK8 assay**

Cells were seeded at a density of 4×10³ cells/well in 96-well plates 24 h after pretreatment. After incubation, 10 μL of CCK-8 reagent (Cell Counting Kit-8; Dojindo Laboratories, Tokyo, Japan) were added to each well according to the instructions. The optical density value (OD) was measured with a microplate reader (Infinite 200 PRO; Tecan, Männedorf, Switzerland) at a wavelength of 450 nm. Each group was set up in three wells, and each measurement was repeated at least three times.

**EdU staining for hepatocytes in vitro**

For in vitro detection, hepatocytes were cultivated on slides. After different interferences, EdU staining and Hoechst 33342 staining were performed using the Cell-Light™ EdU Apollo®567 In Vitro Imaging Kit (C10310-3; RiboBio). The ratios of EdU-positive cells to total cells (Hoechst 33342-positive cells) were calculated.

**Measurement of ROS levels in AML12 cells**
The cells were cultured in 24-well plates and co-treated with CCl₄ (9 mM) and pilocarpine (180 μM) for 24 h at 37°C. On the basis of liver injury model, the 4-DAMP group was treated with 100 nM 4-DAMP for 30 min, and then treated with pilocarpine for 24 h. Finally, the cells were incubated with serum-free medium containing 10 μM DCFH-DA (Beyotime, Shanghai, China) for 30 min. The cells were then washed three times with serum-free medium and observed and imaged with a fluorescence microscope (Olympus, Tokyo, Japan).

Quantitative real-time PCR (qRT-PCR)

Total RNA was extracted from liver tissue or AML12 cells using TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. The quantity and quality of RNA were determined with NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, USA). Complementary DNAs (cDNAs) were synthesized using 0.5 mg of total RNA, oligo(dT)12–18 primers, and a ReverTra Ace quantitative real-time reverse-transcription PCR (qRT-PCR) RT kit (FSQ-101; Toyobo, Osaka, Japan) following manufacturer’s protocol. Gene expression was detected by qRT-PCR using the cDNAs, THUNDERBIRD SYBR qPCR mix reagents (QPS-201; Toyobo) and gene-specific oligonucleotide primers on an ABI 7500 fast real-time PCR system (Applied Biosystems, Foster City, USA). Gene expressions in liver samples and cells were determined using the 2⁻ΔΔCT method. The expression level of GAPDH or U6 was used to normalize the relative gene expressions. Primer sequences are listed in Table 1.

Western blot analysis

Cells were lysed and protein concentration was quantified using a protein assay kit (Beyotime, Shanghai, China). Ten micrograms of total proteins were separated by 12% SDS-PAGE and transferred onto a PVDF membrane. The membrane was blocked with TBST containing 5% skim milk for 2 h at room temperature and then incubated with rabbit polyclonal antibodies against Sp1 (1:1000, NBP2-20460; Novus Biologicals, Littleton, USA), ERK1/2 (1:1000, 4695S; Cell Signaling Technology, Boston, USA), p-ERK1/2 (1:1000, 4370S; Cell Signaling Technology and GAPDH (1:1000, 14C10; Cell Signaling Technology) at 4°C overnight. After washing, the membrane was incubated with HRP-conjugated Rabat-anti-goat IgG (Cell Signaling Technology) for 2 h at room temperature. The signal of the protein band was detected
using ECL reagent (29050; Engreen Biosystem, Beijing, China).

Statistical analysis
All data except the pathological results are expressed as the mean ± SEM. Significant differences in data between the two groups were determined by Student’s t-test and differences between multiple groups were determined by one-way ANOVA using SPSS 17.0 (IBM, Armonk, USA). \( P < 0.05 \) was considered statistically significant.

Results
Protective effect of M\(_3\)R on CCl\(_4\)-induced liver injury in mice
We examined the effects of M\(_3\)R on histopathological changes in CCl\(_4\)-induced liver injury. H&E and Masson’s trichrome staining revealed that the control livers had normal architecture with little fibrous portal expansion. Whereas, CCl\(_4\)-treated livers exhibited massive fatty changes, gross bridge necrosis, and broad infiltration of neutrophils and lymphocytes. CCl\(_4\)-treated livers also showed significant pericentral fibrosis with extensive blue-stained fibers. Compared to the model group, the pilocarpine group showed a significantly attenuated extent of liver injury. However, the attenuated effects of pilocarpine on liver injury were reversed by 4-DAMP (Figure 1A). ELISA results showed that the levels of the hepatocyte injury markers ALT and AST in mouse serum were increased in the CCl\(_4\)-treated group compared with those in the control group. Pilocarpine treatment significantly inhibited ALT and AST levels, whereas pretreatment with 4-DAMP attenuated the effects of pilocarpine (Figure 1B,C). In addition, CCl\(_4\) treatment increased the HYP content compared with the control group. Pilocarpine decreased the HYP content compared with the CCl\(_4\) group, which was reversed by 4-DAMP (Figure 1D). We also found that the mRNA expressions of Coll1α1, α-SMA and TGF-β1, which are fibrosis-related genes, were increased after the incubation with CCl\(_4\). However, their expressions in the pilocarpine-treated group were lower than those in the CCl\(_4\) group, which was reversed by 4-DAMP treatment (Figure 1E–G). These results demonstrate that activation of the M\(_3\)R has a protective effect on CCl\(_4\)-induced liver injury in mice.

Activating M\(_3\)R relieves CCl\(_4\)-induced AML12 injury and promotes proliferation of injured AML12
Previous studies have demonstrated that ERK1/2 is closely related to cell proliferation
Therefore, we postulated that ERK1/2 may mediate the effect of M₃R on the proliferation of injured hepatocytes. MTT assay was performed to determine the optimum concentration of pilocarpine in the treatment of AML12 cells. The survival rate of CCl₄-treated hepatocytes was increased when pilocarpine was administrated at 180 µM (Supplementary Figure S1). qRT-PCR and western blot analysis showed that p-ERK1/2, ERK1 and ERK2 levels were significantly upregulated after treatment with pilocarpine compared to the CCl₄ group, which was reversed by 4-DAMP (Figure 2A–F). There was no significant change in T-ERK1/2 between the groups. Thus, the results indicate that activation of the M₃R promotes phosphorylation of ERK1/2 and further leads to hepatocyte proliferation.

To further explore the role of M₃R in vitro, we evaluated the effect of M₃R on ROS production in the hepatocyte cell line AML12. The data indicated a significant increase in ROS production in CCl₄-treated AML12 cells (Figure 2G). However, pilocarpine treatment reduced intracellular ROS production which was reversed by 4-DAMP. CCK8 assay results showed that after 24 h of pilocarpine treatment, the proliferation of AML12 cells was enhanced, which was reversed by 4-DAMP (Figure 2H). Therefore, these results indicate that the M₃ muscarinic receptor is involved in hepatocyte injury caused by CCl₄.

Sp1 and Gm2199 are involved in M₃R-mediated protection against liver injury
To explore the function and mechanism of Gm2199 in M₃R-mediated protection against liver injury, we measured Gm2199 expression in the liver and AML12 cells treated with CCl₄. Gm2199 was significantly upregulated in the CCl₄ + pilocarpine group in the liver and AML12 cells compared to that in the CCl₄ group. Interestingly, the effect of pilocarpine on Gm2199 was reversed by 4-DAMP (Figure 3A,B). Furthermore, we examined the mRNA and protein levels of the transcription factor Sp1. Pilocarpine significantly upregulated CCl₄-induced downregulation of mRNA and protein levels of Sp1 in AML12 cells, which were effectively reversed by 4-DAMP (Figure 3C,D). We also found that activation of the M₃R decreased the expression of Sp1 in the nucleus (Supplementary Figure S2). Thus, M₃R activation might decrease the content of Sp1 in the nucleus, in addition to directly inhibiting its expression. From the above results, we know that Sp1 and Gm2199 are both involved in M₃R-mediated liver protection.
**Sp1 may potentially regulate Gm2199**

To further determine the relationship between Sp1 and Gm2199, the binding sites of Sp1 and Gm2199 promoter region were predicted using JASPAR (https://jaspar.genereg.net/search?advanced=true). There were nine binding sites with a correlation score above 0.90 (Figure 4A). On this basis, we transfected si-Sp1 specifically into AML12 cells, and the transfection efficiency was satisfactory (Figure 4B). Moreover, Gm2199 expression was upregulated after transfection with si-Sp1 compared with cells transfected with si-NC (Figure 4C). This indicates that Sp1 is likely to regulate Gm2199.

**Effect of Sp1 on hepatocyte proliferation**

Our previous study revealed that Gm2199 can inhibit liver injury through the ERK1/2 pathway [11]. Therefore, to investigate the biological function of Sp1 in hepatocytes, we examined the expression changes of ERK1/2 by qRT-PCR and western blot analysis. It was found that the protein level of Sp1 was increased in CCl4-injured hepatocytes; however, the expression of Sp1 was downregulated after transfection with si-Sp1 (Figure 5A, B). This is consistent with the change in mRNA expression in Figure 4B. Compared with normal cells, phosphorylated ERK1/2 (p-ERK1/2) was significantly downregulated by CCl4-induced hepatocyte injury, while total ERK1/2 (T-ERK1/2) showed no significant change. On this basis, p-ERK1/2 was upregulated in the CCl4 + si-Sp1 group compared to that in the CCl4+si-NC group, and there was no significant change in T-ERK1/2 (Figure 5C–F). Similarly, si-Sp1 reversed the down-regulation of ERK1 and ERK2 mRNAs in AML12 cells caused by CCl4 (Figure 5G, H). CCK-8 assay revealed that CCl4 treatment significantly inhibited cell proliferation, and the number of AML12 cells was 2-fold higher in the CCl4+si-Sp1 stimulation group than in the CCl4+si-NC stimulation group (Figure 5I). Therefore, these results indicate that transfection with si-Sp1 promotes the phosphorylation of ERK1/2 and further leads to hepatocyte proliferation, indicating that Sp1 is involved in liver injury caused by CCl4.

**Identification of miR-212 as a target of Gm2199**

It has been reported that many lncRNAs are ceRNAs for specific miRNAs. To examine whether Gm2199 exerts its function in liver injury as a ceRNA, we utilized the StarBase software and measured the miRNAs predicted to bind with Gm2199. As
shown in Figure 6A, miR-212 was significantly negatively correlated with Gm2199 in liver injury. AML12 cells were transfected with pEGFP-N1 Gm2199, and it was found that Gm2199 overexpression resulted in the repression of miR-212 expression relative to the NC group, indicating that Gm2199 could directly sponge miR-212 (Figure 6A). To further verify the effect of miR-212 and its relationship with Gm2199 in liver injury, AMO-miR-212 was transfected into AML12 cells and its effects on cell proliferation were tested. CCK8 assay showed that AMO-miR-212 increased the proliferation activity of AML12 cells, while its mimic inhibited the cell proliferation activity, and this inhibitory effect could be offset by overexpression of Gm2199 (Figure 6B). The EdU staining assay result was consistent with that of CCK8 assay (Figure 6C). We further found that miR-212 is a potential ERK1/2 regulatory target through TargetScan software (Figure 6D). After successful transfection of mimic-miR-212, we detected the expression changes of p-ERK1/2 and T-ERK1/2 by western blot analysis. Results in Figure 6E showed that miR-212 significantly reduced the level of p-ERK1/2 in AML12 cells compared with the control group. However, there was no significant difference in T-ERK1/2 between the two groups. qRT-PCR showed that the total mRNA levels of ERK1 and ERK2 were downregulated after transfection with mimic-miR-212, and AMO-miR-212 could reverse this phenomenon (Figure 6F). These results suggest that overexpression of miR-212 in normal AML12 cells inhibits cell proliferation and survival by reducing p-ERK1/2 levels. Thus, miR-212 might be involved in the function exerted by Gm2199 in M3R-mediated protection against mouse liver injury.

Discussion

Liver injury, which has an extremely poor prognosis and high mortality, lacks effective therapies. In our previous study, we reported that Gm2199 is downregulated in CCl4-induced liver injury in mice, whereas overexpression of Gm2199 promotes hepatocyte proliferation and alleviates liver injury [11]. In the present study, we found that activating M3R has protective effects on CCl4-induced liver injury in mice. Sp1 and Gm2199 are significantly altered during M3R-mediated protection against liver injury, suggesting that Sp1 and Gm2199 may be involved in protecting the liver. Nevertheless, miR-212 in CCl4-treated AML cells showed the opposite changes. In addition, we found that knockdown of miR-212 stimulates the MAPK signaling pathway activation. These results remind us of a new possible mechanism by which
M₃R protects the liver in CCl₄-induced liver injury.

It has been demonstrated that the muscarinic M₁ subtype is also involved in liver injury in mice. Substantial sequence homology among MR subtypes suggests that M₃Rs are also potential targets for regulating liver injury, however they demonstrate surprising individuality in their responses to stimuli [19-21]. In our study, we observed the effect of M₃R on CCl₄-induced liver injury. Many studies have shown that serum ALT, AST levels and HYP levels are significantly increased during liver injury, indirectly reflecting the degree of liver injury [22]. We found that treatment with CCl₄ significantly increased collagen fiber content and upregulated the expression of fibrosis-related genes such as α-SMA, colla1 and TGF-β1, while treatment with pilocarpine significantly reduced serum ALT and AST levels and liver HYP content in tissues. The M₃R antagonist 4-DAMP reversed these results. These data show that M₃-mACH reduces CCl₄-induced liver injury by reducing fibrosis.

To further explore the possible mechanisms by which M₃Rs are activated to reduce liver injury, we focused on IncRNAs to investigate the role of IncRNAs in liver injury. Many studies have shown that IncRNAs are likely to be used as powerful diagnostic and prognostic indicators and even effective therapeutic targets in related liver diseases [9, 23-25]. Although we have reported that overexpression of IncRNA-Gm2199 can alleviate liver injury [11], the mechanism of Gm2199 in liver injury remains unexplored. In the present study, we found that treatment with pilocarpine significantly increased Gm2199 expression in CCl₄-induced liver injury, which could be reversed by 4-DAMP. Our results indicate that Gm2199 is involved in M₃R-mediated liver protection. miRNA is closely associated with the occurrence of liver diseases such as hepatitis, NAFLD, fibrosis, cirrhosis and HCC [26]. It has been revealed that IncRNAs function as ceRNAs, thereby releasing the miRNA-bound target genes [27-29]. Based on the interactive effect between miRNAs and IncRNAs, we screened out miR-212 which interacts with Gm2199.

The transcription factor Sp1 can regulate the expression of related IncRNAs, such as IncRNA-HOTAIR and IncRNA-HULC in liver cancer [17, 30]. Sp1 can also regulate the expressions of many related factors in the liver, such as TGF-β1, and then regulate the activation of HSCs. Therefore, Sp1 is becoming recognized as a key mediator in liver lesions. In the current study, we found that Sp1 is significantly elevated in the liver injury model, and after activation of the M₃R, Sp1 expression is significantly downregulated. We also confirmed that Sp1 negatively regulates
Gm2199 and exerts a certain influence on hepatocyte proliferation. These findings allowed us to draw up the following signaling pathway as a new mechanism for the long-recognized yet poorly understood in liver injury: Activation of the M₃R can specifically regulate Gm2199 by inhibiting the expression of Sp1. Gm2199 acts as a sponge of miR-212, which can promote the expression of ERK1/2 by inhibiting miR-212 (Figure 7). In conclusion, our results indicate that M₃R may serve as a novel therapeutic target for the treatment of liver injury.

Supplementary Data
Supplementary data is available at Acta Biochimica et Biophysica Sinica online.

Funding
This work was supported by the grants from the Natural Science Foundation of Hainan Province (No. 2019RC225) and the National Natural Science Foundation of China (No. 81960676).

Conflict of Interest
The authors declare that they have no conflict of interest.

References
5. Luo L, Xi C, Xu T, Zhang G, Qun E, Zhang W. Muscarinic receptor mediated signaling pathways in hepatocytes from CCL4 - induced liver fibrotic rat. Eur J


27. Lei H, Gao Y, Xu X. LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. *Acta Biochim Biophys Sin (Shanghai)* 2017, 49: 588-597.


**Figure legends**

**Figure 1. Rescue effect of activating the M3R in damaged livers of mice** (A) External and histomorphological appearance of livers stained with hematoxylin and eosin and Masson’s trichrome. Scale bar: 10 μm. (B-D) Serum ALT and AST contents and liver HYP level in mice. (E–G) qRT-PCR was used to detect the levels of liver injury-related genes including *Col1α1*, α-SMA, and TGF-β1. Data are expressed as the mean±SEM (n=3). *P<0.05 and ***P<0.001 vs control; #P<0.05, ##P<0.01 and ###P<0.001 vs CCl4; @P<0.05, @@P<0.01 and @@@P<0.001 vs CCl4+pilocarpine.

**Figure 2. Effects of activating the M3R on damaged hepatocytes and the expression of ERK1/2** (A,B) qRT-PCR analysis of ERK1 and ERK2 mRNA expressions in AML12 cells. (C–F) The protein expressions of p-ERK1/2 and T-ERK1/2 in AML12 cells with different treatments. (G) Production of intracellular ROS. Scale bars: 20 μm. (H) Cell proliferation was performed by CCK8 assay. Data are expressed as the mean±SEM (n=3). *P<0.05, **P<0.01 and ***P<0.001 vs control; #P<0.05, ##P<0.01 and ###P<0.001 vs CCl4; @P<0.05, @@P<0.01 and @@@P<0.001 vs
CCl₄+pilocarpine.

**Figure 3. Sp1 and Gm2199 are involved in M₃R-mediated liver protection**  (A,B) qRT-PCR analysis of Gm2199 mRNA expression in AML12 cells and liver tissues. (C,D) Representative western blot analysis and qRT-PCR of Sp1 in AML12 cells. Data are expressed as the mean±SEM (n=3). *P<0.05, **P<0.01 and ***P<0.001 vs control; #P<0.05, ##P<0.01 and ###P<0.001 vs CCl₄; @P<0.05 vs CCl₄+pilocarpine.

**Figure 4. The transcription factor Sp1 may potentially regulate Gm2199**  (A) It is predicted by the Jaspar website that there is a binding site for the promoter of Gm2199 and the transcription factor Sp1, and there are 9 sites with a correlation score above 0.9. (B) qRT-PCR was used to detect Sp1 mRNA expression in AML12 cells co-transfected with si-Sp1. (C) qRT-PCR analysis of Gm2199 mRNA of AML12 cells co-transfected with si-Sp1. Data are expressed as the mean±SEM (n=3). **P<0.01 vs control; #P<0.05 and ##P<0.01 vs CCl₄; @@P<0.01 and @@@P<0.001 vs CCl₄+si-Sp1.

**Figure 5. Effect of si-Sp1 on activation of damaged hepatocytes and expression of ERK1/2**  (A–F) Representative western blot analysis results of Sp1, p-ERK1/2 and T-ERK1/2 from control, CCl₄, CCl₄+si-Sp1 and CCl₄+si-NC treated AML12 cells. (G,H) qRT-PCR analysis of ERK1 and ERK2 mRNA expressions in AML12 cells. (I) Hepatocyte proliferation was detected by CCK8 assay. Data are expressed as the mean±SEM (n=3). *P<0.05, **P<0.01 and ***P<0.001 vs control; #P<0.05, ##P<0.01 and ###P<0.001 vs CCl₄; @P<0.05, @@P<0.01 and @@@P<0.001 vs CCl₄+si-Sp1.

**Figure 6. Gm2199 serves as a sponge of miR-212 and ERK1/2 is a target of miR-212**  (A) Bioinformatics analysis of the binding between Gm2199 and miR-212 was performed using Hybird. The expression of miR-212 in cells of each group was detected by qRT-PCR. (B,C) Cell proliferation was performed by CCK8 assay and EdU staining. Scale bars: 20 µm. (D) The putative binding region between ERK1/2 3’UTR and miR-212 was analyzed via TargetScan. (E) Protein expressions of p-ERK1/2 and T-ERK1/2 in each group of AML12 cells were analyzed by western blot analysis. (F) The expressions of ERK1 and ERK2 mRNA in each group of hepatocytes were analyzed by qRT-PCR. Data were expressed as the mean±SEM.
(n=5). *P<0.05, **P<0.01 and ***P<0.001 vs control; #P<0.05 and ###P<0.001 vs AMO-miR-212.

Figure 7. Schematic diagram depicting the proposed signaling mechanisms underlying the effects of M₃R in the setting of liver injury  Activating M₃ receptor can inhibit the expression and nuclear translocation of transcription factor Sp1, and then promote the expression of lncRNA-Gm2199. Gm2199 can promote the expression of ERK1/2 and alleviate liver injury by inhibiting miR-212.
A. Gm2199 expression in liver cells

B. Gm2199 expression in liver tissues

C. Sp1 protein level (relative to GAPDH)

D. Sp1 mRNA expression in liver cells
**Table A**

<table>
<thead>
<tr>
<th>Matrix ID</th>
<th>Name</th>
<th>Score</th>
<th>Relative score</th>
<th>Sequence ID</th>
<th>Start</th>
<th>End</th>
<th>Strand</th>
<th>Predicted sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>13.2935</td>
<td>0.966082163</td>
<td>5</td>
<td>453</td>
<td>462</td>
<td>+</td>
<td>CCCCCCCCCC</td>
</tr>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>12.3964</td>
<td>0.943489426</td>
<td>5</td>
<td>492</td>
<td>501</td>
<td>+</td>
<td>CCCCCCCCCC</td>
</tr>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>12.1807</td>
<td>0.930858467</td>
<td>5</td>
<td>556</td>
<td>565</td>
<td>-</td>
<td>CCCCCTCCTC</td>
</tr>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>11.8365</td>
<td>0.929389862</td>
<td>5</td>
<td>1179</td>
<td>1188</td>
<td>-</td>
<td>CCCCCTCCTC</td>
</tr>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>11.3147</td>
<td>0.916248215</td>
<td>5</td>
<td>1180</td>
<td>1189</td>
<td>-</td>
<td>CCCCCTCCTC</td>
</tr>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>11.867</td>
<td>0.930156696</td>
<td>5</td>
<td>1182</td>
<td>1191</td>
<td>-</td>
<td>CCCCCTCCTC</td>
</tr>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>13.2935</td>
<td>0.966082163</td>
<td>5</td>
<td>1185</td>
<td>1194</td>
<td>-</td>
<td>CCCCCTCCTC</td>
</tr>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>11.9455</td>
<td>0.932135222</td>
<td>5</td>
<td>1378</td>
<td>1387</td>
<td>-</td>
<td>CCCCCTCCTC</td>
</tr>
<tr>
<td>MA0079_2</td>
<td>SP1</td>
<td>13.2935</td>
<td>0.966082163</td>
<td>5</td>
<td>1782</td>
<td>1791</td>
<td>+</td>
<td>CCCCCTCCTC</td>
</tr>
</tbody>
</table>

**Diagram A**

Chromosome 5

Intron RNA Gm2199

**Bar Chart B**

- Sp1 expression in liver cells
  - CCl₄: - + + +
  - si-Sp1: - - + +
  - si-NC: - - - +

**Bar Chart C**

- Gm2199 expression in liver cells
  - CCl₄: - + + +
  - si-Sp1: - - + +
  - si-NC: - - - +
For Peer Review

168x100mm (300 x 300 DPI)
<table>
<thead>
<tr>
<th>Gene name</th>
<th>Primer sequence (5′→3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sp1</td>
<td>Forward ATGAGACAGCAGGGAGAAGGAG&lt;br&gt;Reverse CGGAGATGCTGGAGGATGTCCATATAC</td>
</tr>
<tr>
<td>Gm2199</td>
<td>Forward GCAGACTGGGGCAGGAGAAGC&lt;br&gt;Reverse CACCTCAGCCATTGAAACTCG</td>
</tr>
<tr>
<td>ERK1</td>
<td>Forward TCCAAGGCTAACACAAAATC&lt;br&gt;Reverse AGGTAGTTGGGTCCTTCAT</td>
</tr>
<tr>
<td>ERK2</td>
<td>Forward CACCAACCATTGAGCAAATG&lt;br&gt;Reverse GTTCAGCAGGAGGTGGGAAG</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward GGTTGTCCTCCTGCGAATTCA&lt;br&gt;Reverse TGCTGCAGGGTTTCTTACTCC</td>
</tr>
<tr>
<td>α-SMA</td>
<td>Forward CTCGCCTCTAGCACAACACT&lt;br&gt;Reverse CCCAGGGCTACAAGTTAGGGGT</td>
</tr>
<tr>
<td>Collα1</td>
<td>Forward GATGACGTGCAATGCAATGAA&lt;br&gt;Reverse CCCTCGACTCCTACATCTTCTGA</td>
</tr>
<tr>
<td>TGFβ1</td>
<td>Forward GCCTGAGTGGCTGTCTTCTTA&lt;br&gt;Reverse GCTGAATCGAAAGCCCTGTATT</td>
</tr>
<tr>
<td>miR-212</td>
<td>Forward GCGGCTAACAGTTCTCCAGTC&lt;br&gt;Reverse CAGCCCACAAAAGAGCACAAAT</td>
</tr>
<tr>
<td>U6</td>
<td>Forward GCTTCGGCAGCACATATCTAAAAT&lt;br&gt;Reverse CGCTTCACGAATTTCGCTGTCAT</td>
</tr>
<tr>
<td>miR-212</td>
<td>RT primer CCTGTTGCTCTCAGCACACCAAAGAGCACAATAT&lt;br&gt;TTAGGAGAACAACAGTGGCGT</td>
</tr>
<tr>
<td>U6</td>
<td>RT primer CGCTTCACGAATTTCGCTGTCAT</td>
</tr>
</tbody>
</table>
Supplementary Figure S1. Cytoprotective effect of pilocarpine against CCl₄-induced AML12 cells

Effect of pilocarpine on the viability of AML12 cells with CCl₄ exposure. Cells were incubated with CCl₄ (15 mM, for 24 h) after pretreatment with pilocarpine (60, 100, 140, 180 and 220 µM) for 24 h. The cell viability was determined by the MTT assay. Data are expressed as the mean±SEM of three independent experiments. ***P<0.001 vs control (untreated cells), #P<0.05 vs CCl₄-treated cells.

Supplementary Figure S2. Expression analysis of Sp1 in the nucleus

Representative western blot analysis of Sp1 from control, CCl₄, CCl₄+pilocarpine and CCl₄+pilocarpine+4-DAMP-treated AML12 cells. H3 serves as the loading control.
Highlight

Muscarinic acetylcholine receptor M₃R plays an important role in the regulation of liver injury. However, its regulatory mechanism in hepatocytes is still unknown. Here, we show that activating M₃R can inhibit the expression and nuclear translocation of transcription factor Sp1, and then promote the expression of lncRNA Gm2199. Gm2199 is identified as a sponge of miR-212, which can promote the expression of ERK1/2 and alleviate liver injury by inhibiting miR-212.

- M₃R activity is related to the occurrence and progression of liver injury.
- Gm2199 has a protective effect on liver injury. Activating M₃R can promote the expression of Gm2199 by inhibiting Sp1.
- Gm2199 overexpression induces hepatocyte proliferation by reducing miR-212 expression and promoting ERK1/2 expression.
101x57mm (300 x 300 DPI)